Covidien appoints Bayer's Trudeau president of pharma
This article was originally published in Scrip
Executive Summary
Covidien has appointed Mark Trudeau president of its pharmaceuticals segment and a senior vice-president of the company, effective 1 February. With 25 years' experience of the pharmaceutical industry, Mr Trudeau is currently president and CEO of Bayer Healthcare. He has also served in various positions at Bristol-Myers Squibb, Abbott Laboratories and Lilly. Mr Trudeau succeeds Matthew Harbaugh who served as interim president since 2010 when Timothy Wright resigned, and will continue his role as CFO.